Shopping Cart
Remove All
Your shopping cart is currently empty
Vorsetuzumab mafodotin (Synonyms: SGN-75, h1F6-mcMMAF, Anti-TNFSF7 / CD27L / CD70 Reference Antibody, Anti-Hu...)
Catalog No. T9901A-221 Copy Product Info
🥰Excellent
Vorsetuzumab mafodotin (SGN‑75) is an auristatin-based, CD70-targeted antibody-drug conjugate (ADC), composed of the humanized monoclonal antibody Vorsetuzumab and the ADC cytotoxic molecule MMAF, and exerts antitumor effects.
Vorsetuzumab mafodotin
Copy Product Info🥰Excellent
Catalog No. T9901A-221
Synonyms SGN-75, h1F6-mcMMAF, Anti-TNFSF7 / CD27L / CD70 Reference Antibody, Anti-Human CD70 Recombinant Antibody
Vorsetuzumab mafodotin (SGN‑75) is an auristatin-based, CD70-targeted antibody-drug conjugate (ADC), composed of the humanized monoclonal antibody Vorsetuzumab and the ADC cytotoxic molecule MMAF, and exerts antitumor effects.
Vorsetuzumab mafodotin
Cas No. 1165741-01-4
| Pack Size | Price | USA Stock | Global Stock | Quantity |
|---|---|---|---|---|
| 1 mg | $758 | 2-4 weeks | 2-4 weeks | |
| 5 mg | $2,350 | 2-4 weeks | 2-4 weeks |
For In stock only · Estimated delivery: USA Stock (1-2 days) Global Stock (5-7 days)
Add to Cart
Add to Quotation
With extensive experience in compound synthesis, we can provide rapid custom synthesis services for this product according to your research needs.
For research use only—not for human use. No sales to individuals. Use as intended only.
Resource Download
Product Introduction
Bioactivity
Related Conjugates and Formulations
Antigen Details
Chemical Properties
Antibody Information
Storage & Solubility Information
| Description | Vorsetuzumab mafodotin (SGN‑75) is an auristatin-based, CD70-targeted antibody-drug conjugate (ADC), composed of the humanized monoclonal antibody Vorsetuzumab and the ADC cytotoxic molecule MMAF, and exerts antitumor effects. |
| Targets&IC50 | SKOV3 cells:29 ng/mL |
| In vitro | Vorsetuzumab mafodotin (SGN‑75) induces dose-dependent cytotoxicity after continuous exposure for 96 hours in the concentration range of 0.01 to 10000 ng/mL, with an IC50 of 29 ng/mL [1]. |
| In vivo | Vorsetuzumab mafodotin (SGN‑75) administered intraperitoneally at a dose of 3 mg/kg, four times at 4‑day intervals, can significantly reduce the median tumor volume in mice and effectively inhibit tumor growth [1]. |
| Synonyms | SGN-75, h1F6-mcMMAF, Anti-TNFSF7 / CD27L / CD70 Reference Antibody, Anti-Human CD70 Recombinant Antibody |
| Reactivity | Human |
| Application | Functional assay |
| Antibody Type | Monoclonal, ADC |
| Formulation | Supplied as a sterile solution in a buffered formulation system (e.g., phosphate-, citrate-, or amino acid-based). Please refer to the CoA for lot-specific composition. |
| Endotoxin | <1.0 EU/mg |
| Conjucates | MMAF |
| Gene ID | |
| Uniprot ID | |
| Target | TNFSF7/CD27L/CD70 |
| Molecular Weight | 146.1 kDa |
| Cas No. | 1165741-01-4 |
| Isotype | IgG1 |
| Storage | Store at -20°C Shipping with blue ice. |
Calculator
Preview
Related Tags: buy Vorsetuzumab mafodotin | purchase Vorsetuzumab mafodotin | Vorsetuzumab mafodotin cost | order Vorsetuzumab mafodotin | Vorsetuzumab mafodotin in vivo | Vorsetuzumab mafodotin in vitro | Vorsetuzumab mafodotin molecular weight
Generate Quote
Catalog No.: Cas No.:
Add
| Size | Quantity | Unit Price | Amount | Operation |
|---|
Generate Quote
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.